

Bo Jiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/706165/publications.pdf>

Version: 2024-02-01

11
papers

365
citations

1163117

8
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

929
citing authors

#	ARTICLE	IF	CITATIONS
1	GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner. <i>Cell Death and Disease</i> , 2021, 12, 54.	6.3	17
2	Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. <i>Advanced Science</i> , 2021, 8, e2100250.	11.2	28
3	PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 18343-18354.	3.4	11
4	Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. <i>Journal of Hematology and Oncology</i> , 2020, 13, 80.	17.0	12
5	N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 57-67.	4.1	13
6	BCR/ABL can promote CD19+ cell growth but not render them long-term stemness. <i>Stem Cell Investigation</i> , 2016, 3, 85-85.	3.0	5
7	Roles of palmitoylation and the KKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A. <i>Journal of Hematology and Oncology</i> , 2015, 8, 132.	17.0	20
8	WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation. <i>Molecular Cell</i> , 2015, 57, 662-673.	9.7	242
9	Palmitoyl Acyltransferase DHHC9 Is Required for Efficient Induction of Leukemia By Oncogenic NRAS. <i>Blood</i> , 2014, 124, 893-893.	1.4	1
10	Abstract B49: Role of RAS palmitoyl-acyltransferase DHHC9 in hematopoiesis and NRAS leukemogenesis. , 2014, , .		0
11	8-CPT-cAMP/all- <i>trans</i> retinoic acid targets <i>t</i> (11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RAR α degradation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3495-3500.	7.1	16